Dr. Goggins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-4166
Education & Training
- Johns Hopkins UniversityFellowship, Gastroenterology, 1999 - 2000
- University of Dublin Trinity CollegeClass of 1988
Certifications & Licensure
- MD State Medical License 2001 - 2026
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2018
- America's Top Doctors for Cancer Castle Connolly, 2005-2018
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Join now to see all
Clinical Trials
- Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer Start of enrollment: 2011 Jan 01
- The Cancer of the Pancreas Screening-5 CAPS5)Study Start of enrollment: 2014 Jan 06
Publications & Presentations
PubMed
- 177 citationsGenetic, Immunohistochemical, and Clinical Features of Medullary Carcinoma of the Pancreas : A Newly Described and Characterized EntityRobb E. Wilentz, Michael Goggins, Mark Redston, Victoria Marcus, N. Volkan Adsay
The American Journal of Pathology. 2000-05-01 - 120 citationsPancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.Vanessa L.Z. Gordon-Dseagu, Susan S. Devesa, Michael Goggins, Rachael Z. Stolzenberg-Solomon
International Journal of Epidemiology. 2018-04-01 - 250 citationsRisk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term SurveillanceMarcia I. Canto, Jose Alejandro Almario, Richard D. Schulick, Charles J. Yeo, Alison P. Klein
Gastroenterology. 2018-09-01
Journal Articles
- Pancreatic Cancer Arising in the Remnant Pancreas Is Not Always a Relapse of the Preceding PrimaryJohn L Cameron, Christopher L Wolfgang, Jin He, Matthew J Weiss, Ralph H Hruban, Michael Goggins, Nature
- Single‐Cell Sequencing Defines Genetic Heterogeneity in Pancreatic Cancer Precursor LesionsKevin Waters, Jin He, Christopher L Wolfgang, Ralph H Hruban, Michael G Goggins, Matthew J Weiss, Justin Poling, The Journal of Pathology
- Primordial Germ Cells as a Potential Shared Cell of Origin for Mucinous Cystic Neoplasms of the Pancreas and Mucinous Ovarian TumorsLeona A Doyle, Daniel W Cramer, Michael Goggins, Ronny Drapkin, Jason L Hornick, Kevin M Elias, Michael Birrer, Michelle S Hirsch, The Journal of Pathology
- Join now to see all
Books/Book Chapters
Lectures
- Improving the early detection of pancreatic cancer.Johns Hopkins Oncology Center - 2/19/2014
- The potential clinical utility of markers of pancreatic neoplasia.Yale, New Haven, CT - 11/22/2013
- "The potential clinical utility of markers of pancreatic neoplasia", Visiting ProfessorUniversity of Pennsylvania, Philadelphia - 11/13/2013
- Join now to see all
Other
- Absence of ALK-5 mutations in breast cancer cell lines.Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE, NOgO
1/1/1998 - Absence of Beta-catenin mutations in patients with pancreatic cancer. ( On-Line Publication)Goggins M, Hilgers W, Hruban RH, Kern SE, NOgO
1/1/1997 - Absence of Beta-catenin mutations in patients with breast cancer.Goggins M, Hilgers W, Hruban RH, Kern SE, NOgO
1/1/1997 - Join now to see all
Authored Content
- Q&A: Early Pancreatic Cancer Diagnoses Provide Best Chance for Long-Term SurvivalNovember 2018
- Q&A: Early Pancreatic Cancer Diagnoses Provide Best Chance for Long-Term SurvivalNovember 2018
Press Mentions
- ACVR1C/SMAD2 Signaling Promotes Invasion and Growth in RetinoblastomaNovember 6th, 2018
- BU Researcher Leads Team in ‘Cancer Interception’ ProjectNovember 7th, 2017
- Dream Team Plans to Stop Pancreatic Cancer Before Symptoms OccurOctober 26th, 2017
- Join now to see all
Grant Support
- Using Markers to Improve Pancreatic Cancer ScreeningNIH2013–Present
- Screening for pancreatic neoplasia, the CAPS5 studyAACR-Pancan2013–Present
- Screening markers for high pancreatic cancer susceptibilityNIH2012–Present
- Intercepting pancreatic cancer in high-risk cohortsStand Up to Cancer2018–2022
- Using markers to improve pancreatic cancer screening and surveillanceNCI2016–2021
- Screening Markers For Persons With High Pancreatic Cancer SusceptibilityNational Cancer Institute2007–2011
- Predicting Pancreatic Cancer Responses For A PARP Inhibitor-Based Clinical TrialNational Cancer Institute2009–2010
- Markers Of Early Pancreatic CancerNational Cancer Institute2006–2010
- Classifying Pancreatic Cancers By Methylator PhenotypesNational Cancer Institute2003–2006
- Screening Markers For High Pancreatic CancerNational Cancer Institute2002
- The Panins Of Pancreatitis,Pancreas Cancer And ControlsNational Cancer Institute2001–2002
- Folate Pathway Polymorphisms And Pancreatic Cancer RiskNational Cancer Institute2001–2002
Professional Memberships
- Fellow
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/michael-goggins
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: